drugset
drugset / Trial / NCT00669565

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

NCT00669565 ↗

Phase 2 Completed 46 enrolled Peregrine Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase II, multicenter, single-arm, open-label safety and efficacy study of bavituximab in combination with carboplatin plus paclitaxel in patients with locally advanced or metastatic breast cancer.

Timeline

Start
2008-07
Primary completion
2010-07
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bavituximab Monoclonal antibody 3 mg/kg —
Background Carboplatin Small molecule 2 unknown —
Background Paclitaxel Small molecule 100 mg/m2 —

Indications

breast carcinoma